Published: September 14, 2021  Updated: September 14, 2021 at 7:17 pm EST

Alarmingly, the Biden Administration through the Department of Health and Human Services is now assuming control of the distribution of monoclonal antibodies. The therapy has proven vastly effective against the Coronavirus. It is so effective that the antibodies can prevent hospitalization if taken at the appropriate time in most cases.

The policy change that went into effect Monday is all but certain to result in cuts of the medication to some states, especially seven in the Deep South with high infection rates that have been using about 70 percent of the national supply. Those seven states happen to have Republican leaders who are against the mandate for vaccination. Alabama, Florida, Texas, Mississippi, Tennessee, Georgia and Louisiana are the states that have been using 70 percent of the monoclonal antibody supply in recent weeks, according to HHS data distributed at a meeting last week and a person familiar with the situation.

Monoclonal antibodies are highly effective in preventing hospitalization among people with mild to moderate covid-19, the disease caused by the Coronavirus if given within seven to 10 days after symptoms appear. Administered via a half-hour infusion or four injections, the antibodies mimic the body’s own immune response to the Coronavirus, moving quickly into action while the natural response is gearing up.

Under Biden’s new plan, the government will examine hospitalization data and case rates in states and territories, then determine how much they will receive each week. Then, instead of allowing the States to order the amounts, they need the Federal Government will regulate their usage;

“This system will help maintain equitable distribution, both geographically and temporally, across the country, providing states and territories with consistent, fairly distributed supply over the coming weeks.”

Biden’s regulation of the supply chain is causing people to literally not receive the highly effective treatment, and in turn, that will cause more stress on local hospital systems as the people who could have avoided hospitalization, whether vaccinated or not vaccinated, but showing mild symptoms, could have avoided the hospital altogether and instead received the antibodies. The treatment would normally cost each person $2,100, but it is free because of the pandemic.

Brown's Newsletter

Subscribe to our newsletters and enjoy daily content such as The Daily Paper, Articles, and devotionals right in your inbox.

Currently, the South is undergoing a massive surge of cases as Summer comes to a close and as tourists return home. Tourism alone in the South, a driving force for their local economies, would have significantly increased the potential for cases. Limiting the highly effective therapy to States that disagree with the Administration and Biden’s perspective because of their political views is a glaringly dangerous turn for politics in the United States.

Biden’s Department of Health and Human Services needs to stop the regulation of monoclonal antibodies and allow the states to help themselves.

Works Cited

Lenny Bernstein. “Biden administration moves to stave off shortages of monoclonal antibodies.” The Washington Post. . (2021): . .

Notify of

Inline Feedbacks
View all comments